China Pharma Holdings (CPHI) EBIAT (2016 - 2025)
Historic EBIAT for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$651482.0.
- China Pharma Holdings' EBIAT rose 4172.33% to -$651482.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 3245.82%. This contributed to the annual value of -$4.7 million for FY2024, which is 5383.71% down from last year.
- According to the latest figures from Q3 2025, China Pharma Holdings' EBIAT is -$651482.0, which was up 4172.33% from -$528367.0 recorded in Q2 2025.
- China Pharma Holdings' EBIAT's 5-year high stood at -$475976.0 during Q1 2023, with a 5-year trough of -$1.4 million in Q2 2024.
- Moreover, its 5-year median value for EBIAT was -$826669.0 (2021), whereas its average is -$903544.7.
- Per our database at Business Quant, China Pharma Holdings' EBIAT crashed by 641855.51% in 2021 and then skyrocketed by 6326.01% in 2025.
- Quarter analysis of 5 years shows China Pharma Holdings' EBIAT stood at -$980719.0 in 2021, then dropped by 28.9% to -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then soared by 46.79% to -$651482.0 in 2025.
- Its EBIAT was -$651482.0 in Q3 2025, compared to -$528367.0 in Q2 2025 and -$800000.0 in Q1 2025.